Álvarez-Rangel LE

Idioma: Español
Referencias bibliográficas: 24
Paginas: 75-81
Archivo PDF: 190.29 Kb.

FRAGMENTO

Comentario: la anemia se desarrolla en prácticamente todos los pacientes con enfermedad renal crónica en estadios G4-5 de la KDIGO, con pocas excepciones como la enfermedad renal poliquística. Los niveles de hemoglobina descienden de forma progresiva a partir de que la tasa de filtrado glomerular (TFG) se ubica por debajo de 60 mL/min. De tal forma que la prevalencia de anemia aumenta conforme progresa la enfermedad renal crónica, observándose en 50-60% de los pacientes con TFG entre 15-29 mL/min, y en más de 70% de los pacientes con tasa de filtrado glomerular ‹ 15 mL/min. En este contexto, está claro que todos los pacientes con enfermedad renal crónica en protocolo de estudio como receptores potenciales de trasplante renal requieren evaluación integral de la anemia. En términos generales, el nivel de hemoglobina (Hb) se requiere para evaluar el grado de anemia.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Guías Latinoamericanas de Práctica Clínica Sobre la Prevención, Diagnóstico y Tratamiento de los Estadios 1-5 de la Enfermedad Renal Crónica.

2. Astor B, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with Anemia. Arch Intern Med. 2002; 162: 1401-1408.

3. Amador-Medina LF. Anemia en enfermedad renal crónica. Rev Med Inst Mex Seguro Soc. 2014; 52: 660-665.

4. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 (Suppl 2): 1-47.

5. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006; 47 (suppl. 3): S1-S146.

6. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter Suppl. 2012; 2: 279-335.

7. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013; 62: 860-873.

8. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D et al. Kidney Disease: Improving Global Outcomes guidelines on anemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28: 1346-1359.

9. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016; 89 (1): 28-39.

10. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18 (3): 975-984.

11. Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008; 19: 372-379.

12. Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P et al. Safety of intravenous iron in dialysis: a systematic review and metaanalysis. Clin J Am Soc Nephrol. 2018; 13: 457-467.

13. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019; 380 (5): 447-458.

14. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA et al. Investigators and committees: intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019; 380: 502.

15. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.

16. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.

17. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckard KU et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032.

18. Opelz G, Graver B, Mickey MR, Terasaki P. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation. 1981; 32: 177-183.

19. Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J et al. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant. 2013; 28: 2908-2918.

20. Resse M, Paolillo R, Minucci BP, Costa D, Fiorito C, Santangelo M et al. Effect of single sensitization event of human leukocyte antigen alloinmunization in kidney transplant candidates: a single-center experience. Exp Clin Transplant. 2018; 1: 44-49.

21. Lopes D, Barra T, Malheiro J, Tafulo S, Martins L, Almeida M et al. Effect of different sensitization events on HLA alloimmunization in kidney transplantation candidates. Transplant Proc. 2015; 47: 894-897.

22. Akgul SU, Ciftci HS, Temurhan S, Caliskan Y, Bayraktar A, Tefik T et al. Association between HLA antibodies and different sensitization events in renal transplant candidates. Transplant Proc. 2017; 49: 425-429.

23. Balasubramaniam GS, Morris M, Gupta A, Rebello-Mesa I, Thuraisingham R, Ashman N. Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. Transplantation. 2012; 93: 418-422.

24. Leffell MS, Kim D, Vega RM, Zachary AA, Petersen J, Hart JM et al. Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation. 2014; 97: 525-533.